Randomised, double-blind, clinical investigation to compare orlistat 60 milligram and a customized polyglucosamine, two treatment methods for the management of overweight and obesity

Manfred Stoll, Norman Bitterlich, Umberto Cornelli, Manfred Stoll, Norman Bitterlich, Umberto Cornelli

Abstract

Background: The efficacy of a non-prescription drug to support weight loss programs has yet to be compared. This clinical trial investigates the comparability of orlistat 60 milligram (mg) and polyglucosamine.

Methods: Sixty-four overweight or obese subjects were included in a two-center double-blind study. One center was in Germany [center 1] and the other was in Italy [center 2]. The subjects (26 in center 1 and 38 in center 2) were recommended to follow a calorie deficit of about 2000 kilojoules/day and to increase their physical activity to 3 metabolic equivalent hours (MET h)/day. In both centers, subjects were randomized to receive polyglucosamine (2 tablets x 2) or orlistat (1 capsule x 3) for a period of 12 weeks. Weight loss was considered as a main variable together with the reduction of 5 per cent (%) of body weight (5R). Body Mass Index (BMI) and waist circumference (WC) were taken as secondary variables.

Results: A significant difference in weight loss between the two groups was shown, 6.7 ± 3.14 kilogram (kg) in group polyglucosamine versus 4.8 ± 2.24 kg in group orlistat (t test p < 0.05) respectively; BMI and WC reduction were also more consistent with polyglucosamine treatment than with orlistat treatment (t test p < 0.05). No significant difference was found in the number of subjects who achieved 5R (70% for polyglucosamine and 55% for orlistat group; chi square p > 0.05). The administration of polyglucosamine following energy restriction and increase in physical activity reduces body weight, BMI and WC more efficiently than orlistat.

Conclusions: Even though both groups were instructed to adopt a calorie restricted diet together with increased physical activity an additional weight loss in the polyglucosamine group of 1.6 kilogram (kg) compared to the orlistat group (6.2 ± 3.46 versus 4.6 ± 2.36 kg) in both centers was seen despite the higher consumption of carbohydrates in Italy (center 2). A typical Italian diet is usually high in carbohydrate content whereas Germans tend to consume meals with higher fat content. This leads to the assumption that polyglucosamine limits both fat and carbohydrate absorption which would explain the comparable effective weight reduction in the Italian participants.

Trial registration: Trial registration at ClinicalTrials.gov NCT02529631, registered on Aug 19, 2015 retrospectively registered.

Keywords: L 112; Obesity; Orlistat; Overweight; Polyglucosamine; Weight loss; Weight reduction.

Figures

Fig. 1
Fig. 1
CONSORT Statement Flow Chart
Fig. 2
Fig. 2
Double Dummy Design blister pack
Fig. 3
Fig. 3
ITT percentage of 5-%- Responder, is the percentage of subjects with a body weight reduction of at least 5% compared to baseline
Fig. 4
Fig. 4
PP percentage of 5-%-Responder, is the percentage of subjects with a body weight reduction of at least 5% compared to baseline
Fig. 5
Fig. 5
Comparison of the mean body weight in kg

References

    1. World Health Organisation (WHO), Media centre, Obesity and overweight; Fact sheet No 311, available from Accessed 25 April 2016
    1. Evidenzbasierte Leitlinie Prävention und Therapie der Adipositas, Version 2007, Herausgeber DAG, DDG, DGE, DGEM,; H. Hauner editor, available from Accessed 25 April 2016
    1. Davidson MH, Hauptman J, Di Girolamo M, Foreyt JP, Halsted CH, et al. Weight Control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999;281(3):235–242. doi: 10.1001/jama.281.3.235.
    1. Cornelli U, Belcaro G, Cesarone MR, Cornelli M. Use of polyglucosamine and physical activity to reduce body weight and dyslipidemia in moderately overweight subjects. Minerva Cardioangiol. 2008;56(5 Suppl):71–8.
    1. Bondiolotti G, Bareggi SR, Frega NG, Strabioli S, Cornelli U. Activity of two different polyglucosamines, L112 and FF45, on body weight in male rats. Eur J Pharmacol. 2007;567(1-2):155–8. doi: 10.1016/j.ejphar.2007.03.054.
    1. Bondiolotti G, Cornelli U, Strabbioli RS, Frega NG, Cornelli M, et al. Effect of a polyglucosamine on the body weight of male rats: Mechanisms of action. Food Chemistry. 2011;124:978–982. doi: 10.1016/j.foodchem.2010.07.039.
    1. Cornelli U, Milani L, Perra A. The use of polyglucosamine in the metabolic syndrome control. La Med Biol 2006;4:45-54. L’USO DELLA POLIGLUCOSAMINA NEL CONTROLLO DELLA SINDROME METABOLICA, available from Accessed 03 May 2016
    1. Frankenfield D, Roth-Yousey L, Compher C. Comparison of predictive equation for resting metabolic rate in healthy non obese and obese adults. A systematic review. J Am Diet Assoc May. 2005;105(5):775–789. doi: 10.1016/j.jada.2005.02.005.
    1. Lee IM, Djoussé L, Sesso HD, Lu W, Buring JE. Physical activity and weight gain prevention. JAMA. 2010;303(12):1173–1179. doi: 10.1001/jama.2010.312.
    1. Ainsworth BE, Haskell WL, Leon AS, Jacobs DR, Montoye HR et al. Compendium of physical activities: classification of energy cost of human physical activities. Med Sci Sport Exerc. 1993 Jan;25(1):7180 PMID 8292105 (PubMed)
    1. Summary of the European public assessment report (EPAR) for alli®, European Medicines Agency (EMA), availabe from . Accessed 25 Apr 2016.
    1. Anderson JW, Schwartz SM, Hauptman J, Boldrin M, Rossi M, et al. Low-Dose Orlistat Effects on Body Weight of Mildly to Moderately Overweight Individuals: A 16 Week, Double-Blind, Placebo-Controlled Trial. Ann Pharmacother. 2006;40:1717–1723. doi: 10.1345/aph.1H234.
    1. Rössner S, Sjöström L, Noack R, Meinders AE, Noseda G, and on behalf of the European Orlistat Obesity Study Weight Loss, Weight Maintenance, and Improved Cardiovascular Risk Factors after 2 Years Treatment with Orlistat for Obesity. Obes Res. 2000;8:49–61. doi: 10.1038/oby.2000.8.
    1. Smith SR, Stenlof KS, Greenway FL, McHutchison J, Schwartz SM, et al. Orlistat 60 mg reduces visceral adipose tissue: a 24-week randomized, placebo-controlled, multicenter trial. Obesity. 2011;19:1796–803. doi: 10.1038/oby.2011.143.
    1. Otto C, Stoll M, Heitmann C, Willms G, de Vries F et al. Significant Weight Loss under formoline L112 in Overweight Patients with Type 2 Diabetes. In: Wirth A, editor. formoline-Concept 2008; Neu-Isenburg; LinguaMed Verlags-GmbH, ISBN 13-978-3-928610-52-0, p. 73-92.
    1. Pokhis K, Bitterlich N, Cornelli U, Cassano G. Efficacy of polyglucosamine for weight loss – confirmed in a randomized, double-blind, placebo-controlled clinical investigation. BMC Obesity. 2015;2:25 1. doi: 10.1186/s40608-015-0053-5.
    1. The Real Italian Pasta, Consumption and production of pasta in the world; . Accessed 7 Sept 2016.
    1. Aranda JB, Contreras F, Bagchi D, Preuss HG. Efficacy of a novel chitosan formulation on fecal fat excretion: A double-blind, crossover, placebo-controlled study. J Med. 2002;33:1–4.
    1. Pounis G, Di Castelnuovo A, Constanzo S, Persichillo M, Bonaccio M, Bonnanni A et al. Association of pasta consumption with body mass index and waist-to-hip ratio: results from Moli-sani and INHES studies: Nutrition & Diabetes. 2016;6:e218. doi:10.1038/nutd.2016.20.
    1. Duncan SH, Belenguer A, Holtrop G, Johnstone AM, Flint HJ andLobley GE, Applied and environmental microbiology, American Society for Microbiology. 2007. doi:10.1128/AEM.02340-06.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel